Cardiovascular Diagnosis and prognosis estimation today remain a challenge. Estimates are often inaccurate, time-consuming and many times invasive. General practitioners may fail to recognise the presence of increased risk of suffering a major cardiovascular event. Late diagnosis and inadequate prognosis decreases the chances for successful interventions creating financial and psychological strain for the patient, their families and their doctors. Cardiovascular science still trusts single biochemical markers such as cholesterol, but in the twenty-first century it is possible to know much more about the many alterations leading to atherosclerosis.
We want to change this by making routine and frequent screening for cardiovascular diseases possible for anyone on earth.
Rather than searching for a single molecule that identifies a cardiovascular risk, our test identifies molecular variances in the blood that indicate an increased risk of a cardiovascular event. Imagine measuring all blood RNA changes that a cardiac risk factor may induce at the same time: A powerful, deep and accurate superbiomarker.
This gives MultiplAI the power to:
MultiplAI brings together maturing artificial intelligence algorithms, cost-effective sequencing and remote medicine to detect cardiovascular and other complex diseases and better establish prognosis based on the biological substrate.
It’s time to imagine modern universal remote screening for cardiovascular diseases.
With advances in RNA sequencing, bioinformatic processing and deep learning, we now have the power to measure many biomarkers in the blood.
Our patented RNAseq data transformation process makes it possible to represent the incredible complexity of RNA in highly efficient formats ideal for algorithmic analysis.
Medical Doctor with 20+ years in clinical cardiology. Director of a lab of postdocs with 60+ publications working on cutting-edge cellular and molecular biology. Data scientist and coder looking forward to innovating in medicine.
Molecular biologist and biotech specialist with experience co-founding a bioprinting startup (WeBio). Investigator at FLENI-CONICET with 20 peer-reviewed publications.
Serial entrepreneur, angel investor and advisor to startups with 25+ years of corporate finance and open innovation experience.
Tel Aviv, Israel
Serial entrepreneur and computer scientist with contacts in Europe and Israel, and expertise in data science, engineering and data privacy.
Cambridge, MA, USA
Senior pharmaceutical executive based in Boston with 20+ years of experience in clinical oncology and precision medicine.
3-7 Temple Avenue, Suite 140, Temple Chambers, London, EC4Y 0DA, United Kingdom